Edit Symbol List
Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.
Don't know the stock symbol? Use the
Symbol Lookup tool.
Alphabetize the sort order of my symbols
Investing just got easier…
Sign up now to become a NASDAQ.com member and begin receiving instant notifications when key events occur that affect the stocks you follow.Access Now
Key Stock Data
The current last sale of $48.82 is 10.20% Higher than the 52 week low.
|Intraday||Last 52 Weeks|
|High:||$ 49.55||$ 63.69|
|Low:||$ 48.72||$ 44.30|
ETFs with BMY as a Top 10 Holding*
|Weighting||ETF Name (Symbol)||100-Day Price Change (%)|
|4.48%||SPDR S&P Pharmaceuticals ETF (XPH)||-1.35 (-3.39%)|
|3.95%||First Trust Nasdaq Pharmaceuticals ETF (FTXH)||+0.95 (4.74%)|
|3.93%||iShares U.S. Pharmaceutical ETF (IHE)||+3.38 (2.33%)|
|3.24%||ARK Genomic Revolution ETF (ARKG)||+4.19 (14.87%)|
|3.16%||Global X Longevity Thematic ETF (LNGR)||+0.99 (4.87%)|
|*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change. **Green highlights the top performing ETF by % change in the past 100 days.|
Company Description (as filed with the SEC)
Bristol-Myers Squibb Company was incorporated under the laws of the State of Delaware in August 1933 under the name Bristol-Myers Company, as successor to a New York business started in 1887. In 1989, Bristol-Myers Company changed its name to Bristol-Myers Squibb Company as a result of a merger. We are engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis. Refer to the Summary of Abbreviated Terms at the end of this 2018 Form 10-K for terms used throughout the document. We operate in one segment--BioPharmaceuticals. For additional information about business segments, refer to "Item 8. Financial Statements and Supplementary Data--Note 1. Accounting Policies and Recently Issued Accounting Standards." Our principal strategy is to combine the resources, scale and capability of a pharmaceutical company with the speed and focus on innovation of the biotech industry. ... More ...